Related Experiment Videos
Levodopa therapy and the risk of malignant melanoma
J F Siple1, D C Schneider, W A Wanlass
1Pharmacy Service, Veterans Affairs Medical Center, Portland, OR 97207, USA. siple.jolene@portland.va.gov
Objective:
To evaluate the use of levodopa therapy in patients with Parkinson's disease and malignant melanoma.
Data Sources:
A MEDLINE search (January 1966-September 1999) of English-language articles was conducted. Key search terms included levodopa, melanoma, and Parkinson's disease; 34 case reports were identified.
Data Synthesis:
Carbidopa/levodopa continues to be a mainstay in the treatment of Parkinson's disease. Since the late 1970s, a warning has appeared in the prescribing literature for levodopa regarding the risk of activating malignant melanoma. An evaluation was conducted of the case reports in which a causal relationship between levodopa and melanoma was suggested.
Conclusions:
There is an unlikely association between levodopa and induction or exacerbation of malignant melanoma.
Insights
Levodopa therapy is a primary treatment for Parkinson's disease. However, concerns about its link to malignant melanoma are unlikely, based on a review of case reports.
Area of Science:
- Neurology
- Dermatology
- Pharmacology
Background:
- Levodopa, often combined with carbidopa, is a cornerstone treatment for Parkinson's disease.
- Since the late 1970s, prescribing information for levodopa has included a warning regarding potential activation of malignant melanoma.
Purpose of the Study:
- To evaluate the potential association between levodopa therapy and the development or worsening of malignant melanoma in Parkinson's disease patients.
Main Methods:
- A comprehensive literature search of MEDLINE from January 1966 to September 1999 was performed.
- The search focused on English-language articles using keywords: levodopa, melanoma, and Parkinson's disease.
- Thirty-four case reports suggesting a causal link were identified and analyzed.
Main Results:
- Carbidopa/levodopa remains a critical therapy for Parkinson's disease.
- Analysis of identified case reports did not support a significant causal relationship between levodopa use and melanoma induction or exacerbation.
Conclusions:
- The data suggests an unlikely association between levodopa treatment and the induction or exacerbation of malignant melanoma.
- Levodopa therapy can likely continue to be used for Parkinson's disease without significant concern for melanoma risk.